JACC CardioOncology
Diabetes drug class may protect against cancer therapy-related cardiotoxicity
October 21, 2024
Among patients with T2DM and cancer, use of SGLT2 inhibitors was associated with a significantly decreased risk of cancer therapy–related cardiac dysfunction (CTRCD).
This retrospective analysis included patients ≥18 years of age with T2DM, cancer, exposure to cardiotoxic therapies, and no prior history of cardiomyopathy or heart failure. Patients were categorized by SGLT2 inhibitor use and outcomes were compared over a 12-month follow-up period.
The study included 8,675 propensity-matched patients in each cohort (mean age, ∼65 years; 42% female; 71% White; ∼19% GI malignancy; ∼25% were on anthracyclines). The risk of developing CTRCD was lower among patients prescribed SGLT2 inhibitors (hazard ratio [HR], 0.76; 95% CI, 0.69-0.84). SGLT2 use was also associated with reduced heart failure exacerbations (HR, 0.81; 95% CI, 0.72-0.90), all-cause mortality (HR, 0.67; 95% CI, 0.61-0.74), and all-cause hospitalizations/ED visits (HR, 0.93; 95% CI, 0.89-0.97).
Source:
Bhatti AW, et al. (2024, September 22). JACC CardioOncology. SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes. https://www.sciencedirect.com/science/article/pii/S266608732400276X
TRENDING THIS WEEK